Danny is the Lead, Business Development at ATAI Life Sciences; he primarily focuses on sourcing new investment opportunities in the mental health space. Danny has spent 15+ years in neuroscience and is passionate about identifying innovative therapies with the potential to impact the treatment of mental health disorders.
Prior to ATAI, Danny worked at Eli Lilly for ten years where he began his career as a neuroscience sales representative. Danny was also a neuroscience medical liaison where he regularly interacted with key opinion leaders in various fields of neuroscience and neurology, including depression, schizophrenia, and Alzheimer’s. These interactions largely focused on the scientific exchange of information and exploring potential research collaboration opportunities.
Additionally, for 5 years Danny was engaged in business development activities for various companies. As a consultant, his work ranged from assisting small companies achieve their goals to helping large companies search and evaluate available compounds and companies of interest. Danny also worked at a public biotech company as a business development director searching for investment opportunities in the fields of neuroscience and neurology.
Danny earned a Doctor of Pharmacy (Pharm.D.) degree from Northeastern University and an M.B.A. from London Business School. Danny is a Business Review Board Member for the Alzheimer’s Drug Discovery Foundation.